Dallas, TX – February 23, 2017 - Puration, Inc. (USOTC: PURA) and Alkame Holdings, Inc. (USOTC: ALKM) today announced that the two Companies will partner to introduce a second EVERx Bottled Water product at the upcoming Annual Arnold Sports Festival (formerly the ‘Arnold Classic’ named for Arnold Schwarzenegger) in Columbus, Ohio this week, starting March 2nd, 2017. PURA previously announced the launch of its EVERx CBD Infused Bottled Water to take place at the Arnold. Today, the two companies are announcing that PURA will private label ALKM’s patented Alkaline Water under the EVERx brand name. Both EVERx CBD Infused Bottled Water and EVERx Alkaline Bottled Water will be launched at the Arnold.
Title contender, number three ranked UFC MMA women's bantamweight fighter, Julianna Peña will be the EVERx Brand Spokesperson at the Arnold for both EVERx CBD Infused Bottled Water and EVERx Alkaline Water.
ALKM's patented technology alters the structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. The ALKM technology breaks down the hydrogen bonds, reducing water's cluster size, providing a more efficient delivery system for the CBD in the EVERx CBD Infused Bottled Water, and the ALKM technology includes an optimal alkaline pH level formulated with antioxidants and electrolytes so that the EVERx Alkaline Bottled water can deliver most effective hydration available in the alkaline water market.
To learn more about the EVERx Brand Product Launch at the Arnold Sports Festival, follow the link below:
To learn more about Puration: purationinc.com
Follow Puration on Twitter: Puration710
Visit Puration on Facebook: Facebook.com/puration/
To learn more about Alamke Holdings, Inc.: alkameholdingsinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO